top of page
The Professional Network for Healthcare Experts
Escugen and Sovran expand collaboration to co-develop pan-tumour bispecific ADC
Escugen Biotechnology and Sovran Biosciences have expanded their oncology collaboration with a co-development agreement for a pan-tumour bispecific antibody-drug conjugate.
nuaxia
Sep 172 min read
TScan Therapeutics cuts workforce by 75% and pauses Phase 3 programme in strategic pivot
TScan Therapeutics is cutting approximately 75% of its workforce and pausing further enrolment in its Phase 3 ALLOHA-2 study as it redirects resources towards in vivo cell therapy programmes for solid tumours.
nuaxia
Sep 32 min read
bottom of page